3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Prostatic Neoplasms
22
Breast Neoplasms
21
Polycystic Ovary Syndrome
12
Carcinoma, Non-Small-Cell Lung
11
Colorectal Neoplasms
10
Lung Neoplasms
8
Endometrial Neoplasms
7
Pancreatic Neoplasms
6
Neoplasms
6
Glioblastoma
5
Rectal Neoplasms
4
Melanoma
4
Lymphoma, Large B-Cell, Diffuse
4
Insulin Resistance
4
Adenocarcinoma of Lung
4
Adenocarcinoma
4
Uterine Cervical Neoplasms
3
Leukoplakia, Oral
3
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Obesity
2
Neoplasm Metastasis
2
Liver Neoplasms
2
Leukemia, Myeloid, Acute
2
Hyperandrogenism
2
Esophageal Neoplasms
2
Erythroplasia
2
Endometrial Hyperplasia
2
Diabetes Mellitus
2
Colonic Neoplasms
2
Interventions
Cyclophosphamide
46
fludarabine phosphate
24
Busulfan
22
Peripheral Blood Stem Cell Transplantation
20
Radiotherapy
19
Filgrastim
19
Mycophenolic Acid
18
Antilymphocyte Serum
18
Cyclosporine
17
Whole-Body Irradiation
16
Rituximab
16
Etoposide
16
Methotrexate
15
Melphalan
15
Methylprednisolone
14
Tacrolimus
12
Cytarabine
12
Vincristine
10
Prednisone
10
Doxorubicin
10
Cord Blood Stem Cell Transplantation
10
Thiotepa
6
Granulocyte Colony-Stimulating Factor
6
Leucovorin
5
sargramostim
4
fludarabine
4
Daunorubicin
4
glofitamab
3
Sirolimus
3
Methylprednisolone Hemisuccinate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Dendritic Cell Sarcoma, Interdigitating
×
Metformin
×
Clear all
NCT02531308
2022-09-28
DLBCL
Rush University Medical Center
Phase 2
Terminated
5 enrolled
5 charts